Kukje Pharma Co Ltd (002720.KS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · South Korea · ISIN KR7002720001

Price
3,290.00 KRW
Market cap
69.62 bn KRW
P/E (2025)
12.22
P/S (2025)
0.40
Dividend yield
0.91 %
Net margin
3.25 %
Return on equity (ROE)
5.83 %
Return on assets (ROA)
3.13 %

Kukje Pharma Co Ltd financials

Fiscal year20242025
Revenue156.46 bn KRW175.50 bn KRW
Gross profit82.50 bn KRW93.64 bn KRW
Operating income6.70 bn KRW6.18 bn KRW
EBIT7.82 bn KRW7.35 bn KRW
Net income5.21 bn KRW5.70 bn KRW
Diluted EPS – continuing operations255.63 KRW269.27 KRW

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Kukje Pharma Co Ltd

Kukje Pharma Co., Ltd. engages in manufacturing, importing, exporting, selling, and distributing pharmaceutical products. The company offers pharmaceutical products, including ETC and OTC products, raw materials, intermediates, and side chain products, as well as cosmetics and health care products. Its products include cephalosporins, quinolones, tetracycline, aminoglycosides, macrolides, other antibiotics, ophthalmic, antifungal and antiviral agents, ophthalmic agents, adrenal corticosteroids, CNS and osteoporotic agents, antihistamines, NSAIDS and other analgesics, gastrointestinal and cardiovascular agents, antidiabetics, genitourinary and respiratory agents, other ETC products, and other products. Kukje Pharma Co., Ltd. was founded in 1959 and is headquartered in Seongnam-si, South Korea.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.